Prof Arlene Siefker-Radtke talks about the data presented at ASCO GU 2019 and the potential impact on treatment landscape in metastatic urothelial cancer.
She highlights the abstract sessions, including exciting new information on sacituzumab and pegylated interleukin-2, as well as the potential of free circulating tumour DNA analyses.
Finally, she discusses the implications of the studies presented at ASCO GU and looks to the future for both patient outcomes and current treatment schedules.
|Clinical evidence for the activity of vofatmab in patients with urothelial cancer|
|Therapeutic profile of gemcitabine-carboplatin vs. gemcitabine-oxaliplatin|
|Sacituzumab as a targeted therapy for metastatic urothelial carcinoma|
|Clinical activity of bempegaldesleukin|
|The detection of circulating free DNA in FGFR-mutant tumours|
|Future therapies for bladder cancer patients|
This programme has been supported by an unrestricted educational grant from Janssen Pharmaceutica (A Johnson & Johnson Company).